Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART])

American Journal of Cardiology

Volumn 86, Issue 5, 2000, Pages 550-552

  Daida, Hiroyuki ^a   Kuwabara, Yoichi ^b   Yokoi, Hisashi ^a   Nishikawa, Hideo ^c   Takatsu, Fumimaro ^d   Nakata, Yasuro ^e   Kutsumi, Yasunori ^f   Oshima, Shigeru ^g   Nishiyama, Shinichiro ^h   Ishiwata, Sugao ^h   Kato, Kenichi ⁱ   Nishimura, Shigeyuki ⁱ   Miyauchi, Katsumi ^a   Kanoh, Tatsuji ^j   Yamaguchi, Hiroshi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c ISE RED CROSS HOSPITAL   (Japan)

^d ANJO KOSEI HOSPITAL   (Japan)

^e JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^f UNIVERSITY OF FUKUI HOSPITAL   (Japan)

^g Gunma Cancer Center   (Japan)

^h TORANOMON HOSPITAL   (Japan)

ⁱ YOKOHAMA ROSAI HOSPITAL   (Japan)

^j JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROBUCOL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROBUCOL; PROSPECTIVE STUDIES; RECURRENCE;

EID: 0034283915     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(00)01013-4     Document Type: Article

References (8)

1. Watanabe K., Sekiya M., Ikeda S., Miyagawa M., Hashida K. Preventive effect of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J. 132:1996;23-29.
2. Tardif J.C., Cote G., Lesperance J., Bourassa M., Lambert J., Doucet S., Bilofeau L., Nattel S., Guise P. Probucol, and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 337:1997;365-372.
3. Yokoi H., Daida H., Kuwabara Y., Nishikawa H., Takatsu F., Tomihara H., Nakata Y., Kutsumi Y., Ohshima S., Nishiyama S., Seki A., Kato K., Nishimura S., Kanoh T., Yamaguchi H. Effective of an anitioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty The Probucol Angioplasty Restenosis Trial . J Am Coll Cardiol. 30:1997;855-862.
4. Pocock S. Clinical Trials. 1983;John Wiley, New York.
5. Ryan T.J., King S.B. III, Bauman W.B., McCallister B.D., Kennedy J.W., Smith S.C. Jr, Kereiakes D.J., Ullyot D.J. Guidelines for percutaneous transluminal coronary angioplasty a report of the American College of Cardiology/American Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedure . J Am Coll Cardiol. 22:1993;2033-2054.
6. Cote G., Lesperance J., Bourassa M.G., Perrault J., Harel F., Tardif J.C., Bilodeau L., Doucet S., L'Allier P.L., Tanguay J.F. Probucol treatment redudes the incidence of major clinical events within the first year post PTCA results from the MVP Trial . Circulation. 98:(suppl I):1998;I-512.
7. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., Emmanuelson H., Margo J., Legrand V., Materne P., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
8. Fry E.T.A., Hermiller J.B., Pinkerton C.A. New stent designs form follows function versus function follows form . Curr Opin Cardiol. 13:1998;232-239.